Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals

Clinical Infectious Diseases

Volumn 46, Issue 6, 2008, Pages 941-945

  Mannheimer, Sharon B ^a,i   Wold, Nicholas ^c   Gardner, Edward M ^d   Telzak, Edward E ^b   Hullsiek, Katherine Huppler ^c   Chesney, Margaret ^e   Wu, Albert W ^f   MacArthur, Rodger D ^g   Matts, John ^c   Friedland, Gerald ^h  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; CEREBELLUM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DYSPHAGIA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOOD DISORDER; MOUTH DISCOMFORT; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SYMPTOMATOLOGY; VOMITING; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 40749143163     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/528859     Document Type: Article

References (33)

1. Fellay J, Boubaker K, Ledergerber B, et al.; Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-7.
2. Johnson MO, Stallworth T, Neilands TB. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav 2003; 7:109-17.
3. Silverberg MJ, Gore ME, French AL. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 2004; 39:717-24.
4. Duran S, Spire B, Raffi F, et al; APROCO Cohort Study Group. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001; 2:38-45.
5. Bing EG, Hays RD, Jacobson LP, et al. Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Qual Life Res 2000; 9:55-63.
6. Carrieri P, Spire B, Duran S, et al.; APROCO Study Group. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 32:38-47.
7. Hays RD, Cunningham WE, Sherbourne CD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108:714-22.
8. Lorenz KA, Shapiro MF, Asch SM, Bozzette SA, Hays RD. Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med 2001; 134:854-60.
9. Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers, MA. Quality of life in asymptomatic and symptomatic HIV-infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS 2000; 14:181-7.
10. Mrus JM, Leonard AC, Yi MS, et al. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med. 2006; 21(Suppl 5):39-47.
11. Justice AC, Chang CH, Rabeneck L, Zackin R. Clinical importance of provider-reported HIV symptoms compared with patient-report. Med Care 2001; 39:397-408.
12. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379-86.
13. Cunningham WE, Shapiro MF, Hays RD, et al. Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. Am J Med 1998; 104:129-36.
14. Kilbourne AM, Justice AC, Rollman BL, et al. Clinical importance of HIV and depressive symptoms among veterans with HIV infection. J Gen Intern Med 2002; 17:512-20.
15. MacArthur RD, Chen L, Mayers DL, et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials 2001; 22:176-90.
16. Helfert K, Balsley J, Feinberg J, Hafner R, Pettinelli C. Development of standard parameters for grading severity of adverse experience data from AIDS clinical trials. In: Program and abstracts of the 26th Annual Drug Information Association Annual Conference (San Francisco). Horsham, PA: Drug Information Association, 1990.
17. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.
18. Hurst NP, Ruta DA, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 1998; 37:862-9.
19. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Medical Care 1991; 29:786-98.
20. Han C, Pulling CC, Telke SE, Huppler Hullsiek K. Assessing the utility of five domains in SF-12 Health Status Questionnaire in an AIDS clinical trial. AIDS 2002; 16:431-9.
21. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-33.
22. Ware J, Kosinski M, Keller S. SF-12: How to score the SF-12 physical and mental health summary scales. Lincoln, RI: QualityMetric Incorporated, 1998.
23. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research: how meaningful is it? Pharmacoeconomics 2000; 18:419-23.
24. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15:141-55.
25. Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. AIDS 1998; 12:1495-1502.
26. Revicki DA, Moyle G, Stellbrink HJ, Barker C. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS 1999; 13:851-8.
27. Mrus JM, Sherman KE, Leonard AC, Sherman SN, Mandell KL, Tsevat J. Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one? Med Care 2006; 44:158-66.
28. Mathews WC, McCutchan JA, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care 2000; 38:750-62.
29. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health-System Pharm 2004; 61:2507-22.
30. Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54(Suppl 1):77-90.
31. Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1999; 21:126-33.
32. Bent S, Padula A, Avins AL. Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006; 144,257-61.
33. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 10 October 2006. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed 4 October 2007.